, a filtration, separation and purification manufacturer, recently purchased GeneSystems, a privately held French biotechnology company that has developed a cost-effective and easy-to-use molecular diagnostics platform used for process monitoring. Process monitoring includes the analytical tests required during biopharmaceuticals manufacturing for environmental monitoring, in-process control testing and finished product release testing. Pall believes these tests are receiving more and more regulatory scrutiny and initiative support. The acquisition of GeneSystems, with its patented approach to rapid microbiological detection equipment and disposables, expands Pall's total fluid management capabilities in the biopharmaceuticals process monitoring market; the acquisition also presents the company with opportunities in its environmental, food and beverage, and water markets. Founded in 2000 in Bruz, France, the company quickly gained recognition for its quantitative Legionella diagnostic platform. Since its first product's launch in 2004, GeneSystems has developed systems for the rapid and precise diagnosis of a range of pathogens. These systems employ advanced sample preparation methods and real-time polymerase chain reaction technology to enable fast and high throughput, along with high reproducibility in analysis of multiple DNA targets. The company says its real-time polymerase chain reaction technology detects small quantities of specific micro-organisms, providing results within hours. "We are excited by this acquisition and the increased opportunities it presents for our pharmaceutical, biotechnology, environmental monitoring, quality control and diagnostics programs," says Eric Krasnoff, Pall Corp. Chairman and CEO. "Customers seek better tools for rapid testing and process monitoring. GeneSystems expands our ability to provide total fluid management to meet customer's raw materials, production, testing and environmental requirements."